<div id="readability-page-1"><p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Greenwich LifeSciences today and set a price target of $45.00.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>LeBoyer covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, Ocugen, and Nutriband. According to TipRanks, LeBoyer has an average return of <span>-12.0%</span> and a 26.98% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on Greenwich LifeSciences is a Moderate Buy with an average price target of $45.00.</p></div>

GLSI

<p>Noble Financial analyst Robert LeBoyer reiterated a Buy rating for Greenwich LifeSciences, setting a price target of $45.00. LeBoyer, who covers the Healthcare sector, has an average return of -12.0% and a 26.98% success rate on recommended stocks. The analyst consensus for Greenwich LifeSciences is a Moderate Buy with the same price target.</p>

Greenwich LifeSciences (GLSI) Gets a Buy from Noble Financial